Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Hold rating on Integra Lifesciences (NASDAQ:IART) and lowers the price target from $58 to $54.
May 18, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities analyst maintains a Hold rating on Integra Lifesciences and lowers the price target from $58 to $54.
The news directly mentions Integra Lifesciences (IART) and the analyst's decision to maintain a Hold rating and lower the price target. This may cause some investors to reconsider their positions, but the overall impact on the stock price is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100